Pure Global
NCT06228430

The Bioequivalence Study of Acyclovir 800 mg Tablet in Healthy Thai Volunteers Under Fasting Conditions

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Acyclovir 800 mg Tablet and Reference Product (ZoviraxTM) in Healthy Thai Volunteers Under Fasting Conditions
International Bio service·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Healthy Volunteer
Drug/Device/Intervention
Acyclovir 800 mg Tablet
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
International Bio service
Timeline & enrollment
Phase
Phase 1
Start date
Feb 12, 2024
End date
Feb 22, 2024
Enrollment
40 participants
Primary outcome

Plasma Area Under the Curve (AUC(0 to 36 Hour)) for Acyclovir,Peak Plasma Concentration (Cmax) of Acyclovir

Summary

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic
 Acyclovir 800 mg Tablet and Reference Product (Zovirax™) in Healthy Thai Volunteers under
 Fasting Conditions

ICD-10 classifications
Healthy person accompanying sick personRoutine general health check-up of armed forcesPersons encountering health services in other circumstancesPersons encountering health services in other circumstancesPerson encountering health services in unspecified circumstances
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06228430
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06228430 through Pure Global AI's free database. This Phase 1 trial is sponsored by International Bio service and is currently Not yet recruiting. The study focuses on Healthy Volunteer. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.